Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cerebrospinal Fluid
100%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
100%
MS Method
100%
Sphingolipids
100%
Multiple Sclerosis
42%
Relapsing-remitting multiple Sclerosis
42%
Multiple Sclerosis Treatment
35%
Progressive multiple Sclerosis
35%
Ocrelizumab
28%
Healthy Controls
21%
Disease Activity
14%
Glucosylceramide
14%
Central Nervous System
7%
Demyelination
7%
Fluid Level
7%
Disease States
7%
Tandem Mass Spectrometry
7%
Autoimmune Response
7%
Clinical Disease
7%
Clinical Course
7%
Disease Course
7%
Potential Biomarkers
7%
Degenerative Disease
7%
Multiple Treatments
7%
High-throughput
7%
Nervous System Diseases
7%
Inflammatory Diseases
7%
Human Cerebrospinal Fluid
7%
Multiplexing
7%
Mass Spectrometry Methods
7%
Liquid Chromatography
7%
Multiple Primary
7%
Neuroaxonal Damage
7%
Lipid Signature
7%
C18-ceramide
7%
Neurofilament Heavy
7%
Immunology and Microbiology
Cerebrospinal Fluid
100%
Tandem Mass Spectrometry
100%
Multiple Sclerosis
100%
Liquid Chromatography Mass Spectrometry
100%
Primary Progressive Multiple Sclerosis
41%
Ocrelizumab
33%
Central Nervous System
16%
Autoimmunity
8%
Liquid Chromatography
8%
Neurofilament
8%
Cerebrospinal Fluid Level
8%
Neuroscience
Liquid Chromatography-Mass Spectrometry
100%
Sphingolipid
100%
Multiple Sclerosis
85%
Primary Progressive Multiple Sclerosis
35%
Ocrelizumab
28%
Central Nervous System
14%
Glucosylceramide
14%
Neurofilament
7%
Nervous System Disorder
7%
Mass Spectrometry
7%
Ceramide
7%
Biochemistry, Genetics and Molecular Biology
Liquid Chromatography-Mass Spectrometry
100%
Tandem Mass Spectrometry
100%
Sphingolipid
100%
Ocrelizumab
28%
Neurofilament
7%
Lipid
7%
Cerebrospinal Fluid Level
7%
Autoimmunity
7%
Tandem Mass Spectrometry
7%
Ceramide
7%